New head of business development for Ark

Kassim Kolia will build firm’s manufacturing services business at Finland facility

Ark Therapeutics, a gene-based biopharmaceutical firm with operations in the UK and Finland, has a new head of business development.

Kassim Kolia has taken responsibility for building Ark’s manufacturing services business at its viral process development and manufacturing facility in Kuopio, Finland.

Kolia joins Ark from Eden Biodesign, part of Watson Pharmaceuticals, where, since 2006, he has been responsible for the business development of the firm’s contract development and manufacturing services.

Before joining Eden Biodesign, Kolia was key account manager at Bachem (UK), where he was responsible for business development of cGMP business opportunities in the UK and Ireland. Prior to this, he was cGMP line manager at Lonza Biologics, where he was responsible for the day-to-day running of the manufacturing plant.

You may also like

Manufacturing

Ark opens new manufacturing facility in Finland

<p>UK-based Ark Therapeutics Group has opened its new commercial-scale manufacturing facility (GMP 3) in Kuopio, Finland.</p>
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Regulatory

Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval

The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
Subscribe now